1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2017

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2017

  • February 2017
  • -
  • Global Markets Direct
  • -
  • 135 pages

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Traumatic Stress Disorder (PTSD) – Pipeline Review, H1 2017, provides an overview of the Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline landscape.

Post-traumatic stress disorder (PTSD) is a mental health condition that's triggered by a terrifying event either experiencing it or witnessing it. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants, anti-anxiety and cognitive therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post-Traumatic Stress Disorder (PTSD) – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 3, 17 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 7 and 1 molecules, respectively.

Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2017
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Post-Traumatic Stress Disorder (PTSD) - Overview
Post-Traumatic Stress Disorder (PTSD) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Post-Traumatic Stress Disorder (PTSD) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Post-Traumatic Stress Disorder (PTSD) - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Amorsa Therapeutics Inc
Azevan Pharmaceuticals Inc
Bionomics Ltd
Catalyst Pharmaceuticals Inc
Cerecor Inc
Chronos Therapeutics Ltd
Corcept Therapeutics Inc
Eli Lilly and Company
Embera NeuroTherapeutics Inc
Intra-Cellular Therapies Inc
INVENT Pharmaceuticals Inc
Marinus Pharmaceuticals Inc
Neuralstem Inc
NeuroNascent Inc
Omeros Corp
Otsuka Holdings Co Ltd
Pragma Therapeutics SAS
Synchroneuron Inc
Tonix Pharmaceuticals Holding Corp
TRImaran Pharma Inc
Post-Traumatic Stress Disorder (PTSD) - Drug Profiles
(metyrapone + oxazepam) - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
acamprosate calcium SR - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
ADX-71743 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
AM-3506 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
BNC-210 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
brexpiprazole - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
CERC-501 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
CPP-115 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
CTDP-003 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
D-473 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
ganaxolone - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
IC-87201 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
INV-107 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
KDAC-0001 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
lumateperone tosylate - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
midomafetamine - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
modafinil - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
NNI-351 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
NSI-189 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
PGT-117 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Rycal - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Small Molecule to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Small Molecule to Target GPR83 for CNS and Immunological Disorders - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Small Molecules to Agonize EP1 for Post-Traumatic Stress Disorder - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Small Molecules to Agonize Nociceptin Receptor for Post Traumatic Stress Disorder - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Small Molecules to Antagonize Glucocorticoid Receptor II for Post Traumatic Stress Disorder - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Small Molecules to Antagonize mGluR7 for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Small Molecules to Target NMDA Receptor for Post-Traumatic Stress Disorder - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
SRX-246 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Synthetic Peptide to Antagonize EPHA4 for Post-Traumatic Stress Disorder - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Synthetic Peptide to Target NPSR for Anxiety Disorder - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
tianeptine - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
TNX-102 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Vaccine for CNS Disorders - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
ZL-006 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects
Post-Traumatic Stress Disorder (PTSD) - Discontinued Products
Post-Traumatic Stress Disorder (PTSD) - Product Development Milestones
Featured News and Press Releases
Feb 09, 2017: Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at the 2017 BIO CEO and Investor Conference
Jan 24, 2017: Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at NobleCon13
Jan 10, 2017: Tonix Pharmaceuticals Provides Update on TNX-601 at 9th Annual Biotech Showcase Conference
Jan 10, 2017: Tonix Pharmaceuticals Provides Update on TNX-102 at 9th Annual Biotech Showcase Conference
Jan 05, 2017: Marinus Provides Business Outlook for 2017
Jan 03, 2017: Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at 9th Annual Biotech Showcase Conference
Dec 19, 2016: Tonix Pharmaceuticals' PTSD Phase 3-Ready Drug Candidate, TNX-102 SL, Granted Breakthrough Therapy Designation by the FDA
Dec 08, 2016: Tonix Pharmaceuticals Presented New Clinical Results from Sub-Group Analysis of Phase 2 AtEase Study in Military-Related Posttraumatic Stress Disorder
Dec 02, 2016: Tonix Pharmaceuticals to Present Clinical Data at the 55th Annual Meeting of the American College of Neuropsychopharmacology (ACNP)
Nov 10, 2016: Tonix Pharmaceuticals to Present New Clinical Results from Retrospective Analysis of Phase 2 AtEase Study in Military-Related PTSD
Nov 07, 2016: Tonix Pharmaceuticals to Present Clinical Data at the International Society for Traumatic Stress Studies (ISTSS) 32nd Annual Meeting
Nov 02, 2016: Tonix Pharmaceuticals to Present at 22nd Annual BIO-Europe International Partnering Conference
Nov 01, 2016: Tonix Pharmaceuticals to Present Clinical Data at the 2016 Neuroscience Education Institute (NEI) Psychopharmacology Congress
Oct 27, 2016: Tonix Pharmaceuticals to Present Clinical Data at CNS Summit 2016
Sep 16, 2016: Bionomics to present anti-anxiety drug treatment trial results and ADHD treatment research at ECNP
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Addex Therapeutics Ltd, H1 2017
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Amorsa Therapeutics Inc, H1 2017
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Azevan Pharmaceuticals Inc, H1 2017
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Bionomics Ltd, H1 2017
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Catalyst Pharmaceuticals Inc, H1 2017
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Cerecor Inc, H1 2017
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Chronos Therapeutics Ltd, H1 2017
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Corcept Therapeutics Inc, H1 2017
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Eli Lilly and Company, H1 2017
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Embera NeuroTherapeutics Inc, H1 2017
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Intra-Cellular Therapies Inc, H1 2017
Post-Traumatic Stress Disorder (PTSD) - Pipeline by INVENT Pharmaceuticals Inc, H1 2017
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Marinus Pharmaceuticals Inc, H1 2017
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Neuralstem Inc, H1 2017
Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroNascent Inc, H1 2017
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Omeros Corp, H1 2017
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Otsuka Holdings Co Ltd, H1 2017
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Pragma Therapeutics SAS, H1 2017
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Synchroneuron Inc, H1 2017
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2017
Post-Traumatic Stress Disorder (PTSD) - Pipeline by TRImaran Pharma Inc, H1 2017
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H1 2017
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H1 2017 (Contd..1), H1 2017
Post-Traumatic Stress Disorder (PTSD) - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Autism - Pipeline Review, H1 2017

Autism - Pipeline Review, H1 2017

  • $ 2000
  • Company report
  • February 2017
  • by Global Markets Direct

Autism - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Autism – Pipeline Review, H1 2017, provides an overview of the Autism (Central ...

Alcohol Addiction - Pipeline Review, H1 2017

Alcohol Addiction - Pipeline Review, H1 2017

  • $ 2000
  • Company report
  • February 2017
  • by Global Markets Direct

Alcohol Addiction - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alcohol Addiction – Pipeline Review, H1 2017, provides an overview ...

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H2 2016

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • November 2016
  • by Global Markets Direct

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H2 ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.